Quick Answer
SAB Biotherapeutics, Inc. reported Shares Outstanding of 47.61 million shares for fiscal year 2025.
SAB Biotherapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 47.61M | +412.5% |
| 2024 | 9.29M | +0.7% |
| 2023 | 9.23M | +83.0% |
| 2022 | 5.04M | -88.3% |
| 2022 | 43.03M | +0.2% |
| 2022 | 42.96M | -1.2% |
| 2021 | 43.49M | +67.4% |
| 2020 | 25.97M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 47.49M | +414.6% | +411.1% |
| June 30, 2025 | 9.29M | +0.7% | +0.0% |
| March 31, 2025 | 9.29M | +0.7% | +0.0% |
| December 31, 2024 | 9.29M | +0.7% | +0.6% |
| September 30, 2024 | 9.23M | -82.4% | +0.0% |
| June 30, 2024 | 9.23M | -82.4% | +0.0% |
| March 31, 2024 | 9.23M | -81.7% | +0.0% |
| December 31, 2023 | 9.23M | -81.7% | -82.4% |
- SAB Biotherapeutics, Inc. showed an increase of +412.5% in Shares Outstanding compared to the prior fiscal year.
- Over the 2020–2025 period, SAB Biotherapeutics, Inc.’s shares outstanding has grown by 83.3% (from 25.97 million shares to 47.61 million shares).
- The most recent figure is from SAB Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: